Serum lipoprotein levels in takotsubo cardiomyopathy vs. myocardial infarction

Gaddam, Sainath; Nimmagadda, Krishna C.; Nagrani, Tarun; Naqi, Muniba; Wetz, Robert V.; Weiserbs, Kera F.; McCord, Donald; Ghavami, Foad; Gala, Bhavesh; Lafferty, James C.
January 2011
International Archives of Medicine;2011, Vol. 4 Issue 1, p14
Academic Journal
Background: In the setting of myocardial infarction (MI) or acute coronary syndrome (ACS), current guidelines recommend early and aggressive lipid lowering therapy with statins, irrespective of the baseline lipoprotein levels. Takotsubo cardiomyopathy (TCM) patients have a clinical presentation similar to myocardial infarction and thus receive early and aggressive statin therapy during their initial hospitalization. However, the pathology of TCM is not atherosclerotic coronary artery disease and hence we assumed the lipid profiles in TCM would be healthier than coronary artery disease patients. Methods: In this retrospective study, we assessed fasting serum lipoprotein levels of ten TCM patients and compared them with forty, age and sex-matched myocardial infarction (MI) patients. Results: Comparing serum lipoprotein levels of TCM with MI group, there was no significant difference in mean total cholesterol between the two groups (174.5 mg/dL vs. 197.6 mg/dL, p = 0.12). However, in the TCM group, mean HDL-C was significantly higher (66.87 mg/dL vs. 36.5 mg/dL, p = 0.008), the mean LDL-C was significantly lower (89.7 mg/dL vs. 128.9 mg/dL, p = 0.0002), and mean triglycerides was also significantly lower (65.2 mg/dL vs. 166.8 mg/dL, p < 0.0001). Conclusions: In this study, TCM patients in comparison to MI patients had significantly higher levels of HDL-C, lower levels of LDL-C levels and triglycerides. The lipid profiles in TCM were consistent with the underlying pathology of non-atherosclerotic, non-obstructive coronary artery disease. As lipoproteins in most TCM patients were within the optimal range, we recommend an individual assessment of lipid profiles along with their coronary heart disease risk factors for considering long term lipid-lowering therapy. A finding of hyperalphalipoproteinemia or hypotriglyceridemia in 40% of TCM patients is novel but this association needs to be confirmed in future studies with larger sample sizes. These findings may provide clues in understanding the pathogenesis of takotsubo cardiomyopathy.


Related Articles

  • Guidelines: New Lows for LDL Target Levels. Mitka, Mike // JAMA: Journal of the American Medical Association;8/25/2004, Vol. 292 Issue 8, p911 

    Reports on an update of key cholesterol level guidelines. How the new guidelines further reduce the safe level of LDL-C or bad cholesterol for all patients; Determination of the National Cholesterol Education Program that patients at risk for heart attacks need to lower their LDL further than...

  • 2008 - Review: Statins are effective for prevention of cardiovascular events in patients without coronary heart disease. McAlister, Finlay A. // ACP Journal Club;4/21/2009, Vol. 150 Issue 4, p3 

    The article discusses whether statins are effective for primary prevention of cardiovascular (CV) events. Medical studies comparing statins with placebo, standard therapy, or no treatment for primary prevention were taken into account. Meta-analysis showed that statins reduces all-cause...

  • The Miracle of Niacin. Agatston, Arthur // Prevention;May2009, Vol. 61 Issue 5, p34 

    The article discusses a University of Washington study that shows the benefits of high doses of niacin when taken with statin drugs in lowering the risk factors for heart attack. When taken with statin drugs, niacin raises HDL cholesterol and lowers triglycerides, enlarges the smallest particles...

  • Dr Foster's case notes.  // BMJ: British Medical Journal (International Edition);9/18/2004, Vol. 329 Issue 7467, p645 

    Examines the relationship between the prescribing of lipid regulating drugs or statins to the number of admissions for myocardial infarction in England. Conduct of the study; Finding that the large increase in the cost and volume of the prescribing of lipid regulating drugs has been associated...

  • Early initiation of statins following ACS does not improve outcomes.  // Journal of Family Practice;Aug2006, Vol. 55 Issue 8, p664 

    The article presents a study on whether early initiation of statins following the onset of acute coronary syndromes (ACS) will reduce the short-term risk of death, recurrent myocardial infarction or stroke. The study was carried out through meta-analysis of randomized controlled trials. The...

  • Inflammatory findings. Comarow, Avery // U.S. News & World Report;1/17/2005, Vol. 138 Issue 2, p74 

    Discusses the idea that doctors should be aggressive in prescribing stains for heart attack patients. The role of C-reactive protein as a signal of inflammation associated with coronary artery disease; Research by Christopher Cannon, cardiologist at Brigham and Women's Hospital in Boston;...

  • Serum cholesterol as a risk factor for coronary heart disease revisited. Rossouw, J. E. // South African Journal of Clinical Nutrition;2015, Vol. 28 Issue 1, p34 

    The biology of lipoproteins and lipoprotein particles as mediators of atherosclerosis has been documented extensively. Numerous prospective epidemiological studies have shown a robust relationship between low-density lipoprotein (LDL) cholesterol, or particles bearing apolipoprotein B, and...

  • Fenofibrate: A Review of its Use in Primary Dyslipidaemia, the Metabolic Syndrome and Type 2 Diabetes Mellitus. Keating, Gillian M.; Croom, Katherine F. // Drugs;2007, Vol. 67 Issue 1, p121 

    Fenofibrate is a fibric acid derivative indicated for use in the treatment of primary hypercholesterolaemia, mixed dyslipidaemia and hypertriglyceridaemia in adults who have not responded to nonpharmacological measures. Its lipid-modifying effects are mediated by activation of peroxisome...

  • What Is the Relationship Between Myocardial Perfusion Imaging and Coronary Artery Disease Risk Factors and Markers of Inflammation? Fleming, Richard M.; Harrington, Gordon M. // Angiology;Feb/Mar2008, Vol. 59 Issue 1, p16 

    The treatment of coronary artery disease (CAD) is clinically measured by monitoring changes in venous lipids and inflammatory markers. There is currently no established quantified relationship between coronary flow reserve and markers of inflammatory CAD. A total of 120 men and women underwent...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics